Polyrizon Ltd. Ordinary Shares (PLRZ)

About PLRZ

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker;…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

2

Website

polyrizon-biotech.com/

Fundamentals

1-day range

$12.22$13.15

Market cap

$19.82M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-5.64

Dividend yield

—

Beta

0.56

Avg. volume

52.5K

Polyrizon Ltd. Ordinary Shares Competitors

Chosen by industry and closest market cap.

• PLRZ

  Polyrizon Ltd. Ordinary Shares

  $12.7

  ▼ 0.78%
  Market cap $19.82MP/E —
  $2.88$18.2
• ALLR

  Allarity Therapeutics Inc. Common Stock

  $1.41

  ▲ 2.17%
  Market cap $19.64MP/E —
  $0.769$2.06
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $20.34MP/E —
  $0.8099$2.46
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.17MP/E —
  $0.72$3.78
• SKYE

  Skye Bioscience Inc. Common Stock

  $1.81

  ▼ 7.18%
  Market cap $20.53MP/E —
  $1.84$39.92
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $18.41MP/E —
  $1.83$24.6
• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.24MP/E —
  $3.19$21.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Polyrizon Completes Contracting With Fourth, Fifth Clinical Facilities Participating In Its Clinical Trial Of NASARIX Allergy Blocker
  benzinga · 8/20/2026
• Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
  Yahoo · 8/20/2026
• Polyrizon Completes Contracting With Fourth, Fifth Clinical Facilities Participating In Its Clinical Trial Of NASARIX Allergy Blocker
  Benzinga · 8/20/2026

• Izraeli Tomer · March 31, 2026 · Sale

  500 @ $11.85
• Adler Oz · March 31, 2026 · Sale

  3.3K @ $12.05
• Carmel Liron · March 31, 2026 · Sale

  942 @ $12.36
• Izraeli Tomer · March 30, 2026 · Sale

  3.9K @ $10.9
• Turgeman Tidhar · March 30, 2026 · Sale

  2.9K @ $10.9
• Carmel Liron · March 30, 2026 · Sale

  100 @ $11